Deep understanding of the genomic and immunological differences between Chinese and
Western lung cancer patients is of great importance for target therapy selection and …

Lung cancer, the leading cause of cancer-related deaths worldwide, is a heterogeneous
disease comprising multiple histologic subtypes that harbor disparate mutational profiles …

Chinese lung cancer patients have distinct epidemiologic and genomic features,
highlighting the presence of specific etiologic mechanisms other than smoking. Here, we …

BACKGROUND. Immune checkpoint blockade improves survival in a subset of patients with
non–small-cell lung cancer (NSCLC), but robust biomarkers that predict response to PD-1 …

Introduction To depict the genomic landscape of Chinese early-stage lung squamous cell
carcinoma (LUSC) and investigate its correlation with tumor mutation burden (TMB), PD-L1 …

Objectives This study aimed to explore the novel biomarkers for immune checkpoint inhibitor
(ICI) responses in non‐small cell lung cancer (NSCLC) by integrating genomic profiling …

Background Lung squamous cell carcinoma (LUSC) accounts for 20–30% of non-small cell
lung cancers (NSCLCs). There are limited treatment strategies for LUSC in part due to our …

ABSTRACT Background Lung adenocarcinomas (LUADs) lead to the majority of deaths
attributable to lung cancer. We performed whole-exome sequencing (WES) and immune …

Background Immune checkpoint blockade (ICB) therapy has revolutionized the treatment of
lung squamous cell carcinoma (LUSC). However, a significant proportion of patients with …

Lung adenocarcinoma (LUAD) harboring EGFR mutations prevails in Asian population.
However, the inter-patient and intra-tumor heterogeneity has not been addressed at single …